bezafibrate has been researched along with Cardiomyopathies in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, MT; Heyman, A; Hornby, B; Jefferies, J; Pu, WT; Takemoto, C; Thompson, R; Vernon, HJ; Wang, S | 1 |
| Glukhov, AI; Javadov, S; Khuchua, Z; Strauss, AW | 1 |
| Andresen, BS; Bastin, J; Benoist, JF; Boutron, A; de Lonlay, P; Djouadi, F; Ferdinandusse, S; Fukao, T; Habarou, F; Le Bachelier, C; Olpin, S; Schlemmer, D; Strauss, AW; Visser, G; Wanders, RJ; Yamaguchi, S | 1 |
| Glukhov, AV; Huang, Y; James, JF; Javadov, S; Jefferies, JL; Khuchua, Z; Moore, V; Phoon, CK; Powers, C; Ren, M; Schafer, C; Strauss, AW; Vaz, FM | 1 |
2 review(s) available for bezafibrate and Cardiomyopathies
| Article | Year |
|---|---|
Current and future treatment approaches for Barth syndrome.
Topics: Acyltransferases; Animals; Barth Syndrome; Bezafibrate; Cardiolipins; Cardiomyopathies; Clinical Trials as Topic; Enzyme Therapy; Genetic Therapy; Humans; Mice; Muscular Diseases; Neutropenia; Oligopeptides; Peroxisome Proliferator-Activated Receptors | 2022 |
Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Bezafibrate; Cardiomyopathies; Cardiotonic Agents; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Heart Failure; Humans; Hypolipidemic Agents; Lipid Metabolism; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; Signal Transduction | 2018 |
2 other study(ies) available for bezafibrate and Cardiomyopathies
| Article | Year |
|---|---|
Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate.
Topics: Bezafibrate; Cardiomyopathies; Cell Line; Fibroblasts; Genotype; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Mitochondrial Myopathies; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Mitochondrial Trifunctional Protein, beta Subunit; Mutation; Nervous System Diseases; Rhabdomyolysis | 2016 |
The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
Topics: Animals; Barth Syndrome; Bezafibrate; Blotting, Western; Cardiolipins; Cardiomyopathies; Disease Models, Animal; Echocardiography; Female; Male; Mice; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction | 2017 |